Onyvax Ltd.

Conducts research and development for marketing cell-based vaccines and human monoclonal antibody against CD55 in tumour cells. Includes explanation of products in pipeline, and clinical studies in phase II of prostate cancer vaccine at Bournemouth, and their contacts in London, UK.